ArticleVeterinary research communications2025
Bacillus velezensis MFF 2.2-derived lipopeptides modulate gut immune response in BALB/c mice maintaining mucosal integrity and systemic safety.
Article in Veterinary research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Microbe-Derived Antimicrobial Peptides: Immunomodulation and Gut Microbiota Homeostasis.Microorganisms · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Bacillus-derived lipopeptides, particularly surfactin (SF), are known for their antimicrobial and immunomodulatory properties, making them promising candidates for applications in veterinary medicine. This study investigated the immunomodulatory, cytotoxic, and genotoxic effects of a lipopeptide extract (LPE) derived from Bacillus velezensis MFF 2.2, containing SF, using an in vivo murine model. Four groups of BALB/c mice (n = 6 per group) were orally administered daily doses of: (1) saline solution (control), (2) 60 μg/mL SF standard, (3) 40 μg/mL LPE, and (4) 60 μg/mL LPE, over a 10-day period. Assessments included changes in body weight, histopathological analysis of liver, kidney, and small intestine tissues, as well as evaluation of cytotoxic and genotoxic effects. LPE treatment was well-tolerated, with no significant changes in body weight, organ histopathology, or bone marrow toxicity. Both SF and LPE significantly increased goblet cell counts (P < 0.05), while LPE reduced IFN-γ levels and increased the IL- 10/IFN-γ ratio, suggesting an anti-inflammatory response (P < 0.05). TNF-α and IL- 10 levels remained unchanged, and no significant differences were observed in intraepithelial lymphocyte counts. These findings suggest that LPE derived from B. velezensis MFF 2.2 is safe and promotes immunomodulatory effects, supporting its potential as a therapeutic agent in inflammatory conditions.
Indexed as
Identifiers
40192874What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.